Science & ResearchJul 22, 2026
AI-Driven Design of Nanobinders Targeting the TSLPR Heterodimer Interface to Suppress Type 2 Inflammatory Signaling
Aberrant thymic stromal lymphopoietin (TSLP) signaling is a central driver of type 2 inflammatory diseases, yet the only approved TSLP-targeted therapy is a 150 kDa monoclonal antibody whose bulky format limits tissue penetration and pre…
Aberrant thymic stromal lymphopoietin (TSLP) signaling is a central driver of type 2 inflammatory diseases, yet the only approved TSLP-targeted therapy is a 150 kDa monoclonal antibody whose bulky format limits tissue penetration and precludes inhaled delivery. Here, we report…
Sign in to learn & save →
The frontier is open to all. Sign in to learn this from first principles and save it to your knowledge base.